Humana stock plunged 13.49% in premarket trading after the Trump administration proposed a net average Medicare Advantage payment increase of just 0.09% for 2027, far below Wall Street expectations of 4–6%. The proposal, which would effectively freeze aggregate payments for the nation’s 5,600 Medicare Advantage plans, immediately erased approximately $3.2 billion in Humana’s market value based on its premarket capitalization. Analysts at Morgan Stanley and Barclays downgraded Humana’s outlook, citing heightened regulatory risk and projecting a 150-basis-point compression in adjusted medical margin if the proposal is finalized. The broader managed care sector was also hit hard, with UnitedHealth Group down 8.7%, CVS Health off 9.2% and Elevance Health declining 7.5% in early trading, underscoring investor concern over reimbursement trends in the government program that covers more than 30 million beneficiaries.

In a strategic philanthropic move, Humana announced the launch of a $3 million scholarship endowment for Xavier Ochsner College of Medicine in Louisiana. The fund will provide full-tuition awards to 20 students over four years, targeting candidates from rural parishes with documented physician shortages. Humana expects the program to bolster the state’s primary care and cardiology workforce by 15% by 2030, improving access for an estimated 120,000 underinsured residents. Company executives highlighted that every dollar invested in medical education yields up to $2.50 in economic benefit for local communities, and they plan to track graduate retention rates and patient outcomes through an annual report to stakeholders.

Humana has entered a first-of-its-kind partnership with Carda Health, a virtual cardiac and pulmonary rehabilitation provider, to deliver home-based rehab services to its Medicare Advantage and commercial members across all 50 states. Under the agreement, Humana will co-fund a pilot program covering 5,000 patients in its CenterWell network during the first year, with an expected 12% reduction in 30-day readmission rates and a projected $18 million in avoidable acute-care costs. Carda’s model combines live-monitored exercise sessions, nutrition and medication follow-ups, and functional capacity assessments through a proprietary digital platform, overseen by a multidisciplinary team of clinicians. Early data from Carda’s existing partnerships show a 92% program completion rate and a 28% improvement in patients’ six-minute walk test performance.